Human TRAILR4/TNFRSF10D Antibody

TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody.

In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND₅₀ is typically 0.3-1.8 µg/mL.

Detection of Human TRAILR4/TNFRSF10D/DcR2 by Flow Cytometry

Flow cytometry studies of scFv-Fc-scTRAIL molecules and Fc-scTRAIL on Colo205 and HCT116 cells(A) Expression levels of EGFR, HER2, HER3, EpCAM, and TRAIL-receptors were investigated after treatment of the cells with medium or 250 ng/ml BZB for 16 h. (B) Serial dilutions of the molecules were analyzed. (C) 20 nM scTRAIL units were analyzed after preincubation of the cells with PBA or a 200-fold molar excess of the respective blocking antibody. Binding of Fc-scTRAIL was measured in the presence of all blocking antibodies separately and is here represented as the mean of blocking with all different antibodies. Bound molecules were detected via anti-FLAG-PE. relative MFI, relative median fluorescence intensity. Pairwise comparisons were performed by unpaired t test (two-tailed; *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05). Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.24379), licensed under a CC-BY license. Not internally tested by R&D Systems.